Literature DB >> 11356961

Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

E G Cormier1, D N Tran, L Yukhayeva, W C Olson, T Dragic.   

Abstract

CD4 and CCR5 mediate fusion and entry of R5 human immunodeficiency virus type 1 (HIV-1) strains. Sulfotyrosine and other negatively charged residues in the CCR5 amino-terminal domain (Nt) are crucial for gp120 binding and viral entry. We previously showed that a soluble gp120-CD4 complex specifically binds to a peptide corresponding to CCR5 Nt residues 2 to 18, with sulfotyrosines in positions 10 and 14. This sulfopeptide also inhibits soluble gp120-CD4 binding to cell surface CCR5 as well as infection by an R5 virus. Here we show that residues 10 to 18 constitute the minimal domain of the CCR5 Nt that is able to specifically interact with soluble gp120-CD4 complexes. In addition to sulfotyrosines in positions 10 and 14, negatively charged residues in positions 11 and 18 participate in this interaction. Furthermore, the CCR5 Nt binds to a CD4-induced surface on gp120 that is composed of conserved residues in the V3 loop stem and the C4 domain. Binding of gp120 to cell surface CCR5 is further influenced by residues in the crown of the V3 loop, C1, C2, and C3. Our data suggest that gp120 docking to CCR5 is a multistep process involving several independent regions of the envelope glycoprotein and the coreceptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356961      PMCID: PMC114266          DOI: 10.1128/JVI.75.12.5541-5549.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  The second extracellular loop of CCR5 is the major determinant of ligand specificity.

Authors:  M Samson; G LaRosa; F Libert; P Paindavoine; M Detheux; G Vassart; M Parmentier
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

2.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity.

Authors:  J Rucker; M Samson; B J Doranz; F Libert; J F Berson; Y Yi; R J Smyth; R G Collman; C C Broder; G Vassart; R W Doms; M Parmentier
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

5.  Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

Authors:  R E Atchison; J Gosling; F S Monteclaro; C Franci; L Digilio; I F Charo; M A Goldsmith
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

6.  Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.

Authors:  L Picard; G Simmons; C A Power; A Meyer; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; A Cara; R C Gallo; P Lusso
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

8.  Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.

Authors:  B J Doranz; Z H Lu; J Rucker; T Y Zhang; M Sharron; Y H Cen; Z X Wang; H H Guo; J G Du; M A Accavitti; R W Doms; S C Peiper
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 9.  Selectivity and antagonism of chemokine receptors.

Authors:  T N Wells; C A Power; M Lusti-Narasimhan; A J Hoogewerf; R M Cooke; C W Chung; M C Peitsch; A E Proudfoot
Journal:  J Leukoc Biol       Date:  1996-01       Impact factor: 4.962

10.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

View more
  76 in total

1.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Authors:  Cajetan Dogo-Isonagie; Son Lam; Elena Gustchina; Priyamvada Acharya; Yongping Yang; Syed Shahzad-ul-Hussan; G Marius Clore; Peter D Kwong; Carole A Bewley
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

3.  HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Authors:  Jennifer M Pfaff; Craig B Wilen; Jessamina E Harrison; James F Demarest; Benhur Lee; Robert W Doms; John C Tilton
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

4.  Conserved determinants of enhanced CCR5 binding in the human immunodeficiency virus subtype D envelope third variable loop.

Authors:  Samaporn Teeravechyan; M Essex; Tun-Hou Lee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

5.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

Review 7.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

8.  Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120.

Authors:  Evan T Brower; Arne Schön; Jeffrey C Klein; Ernesto Freire
Journal:  Biochemistry       Date:  2009-02-03       Impact factor: 3.162

9.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.

Authors:  Christoph Seibert; Martine Cadene; Anthony Sanfiz; Brian T Chait; Thomas P Sakmar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.